The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.
What can we help you find?
Attendees at the McKesson ideaShare had the chance to hear about women pharmacists and the challenges, successes, and opportunities they have in a session presented by Suzanne Soliman, PharmD.
The effectiveness and safety of bremelanotide were studied in a pair of 24-week, randomized, double-blind, placebo-controlled trials in 1247 premenopausal women with acquired, generalized HSDD.
A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.
Contraceptives are both a popular and effective birth control method, and Medicaid fully covers them for its beneficiaries.
Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.
This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.
The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.
Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
The action requires the company to revise safety information that women and their health care professionals need when considering use of the drug.
Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.
This therapy is expected to become available in late June.
Indicating for preventing pregnancy, a statement from the FDA said that loss of efficacy is possible if the user misses tablets.